Presentation is loading. Please wait.

Presentation is loading. Please wait.

Utility of the Seattle Heart Failure Model in patients with cardiac resynchronization therapy and implantable cardioverter defibrillator referred for.

Published byRoderick Gilbert Modified over 6 years ago

Similar presentations

Presentation on theme: "Utility of the Seattle Heart Failure Model in patients with cardiac resynchronization therapy and implantable cardioverter defibrillator referred for."— Presentation transcript:

1 Utility of the Seattle Heart Failure Model in patients with cardiac resynchronization therapy and implantable cardioverter defibrillator referred for heart transplantation  Ulrik Sartipy, MD, PhD, Ayumi Goda, MD, Melana Yuzefpolskaya, MD, Donna M. Mancini, MD, Lars H. Lund, MD, PhD  American Heart Journal  Volume 168, Issue 3, Pages (September 2014) DOI: /j.ahj Copyright © 2014 Mosby, Inc. Terms and Conditions

2 Figure 1 Event-free survival for SHFM risk strata. Kaplan-Meier event-free survival for SHFM low-, medium-, and high-risk strata in 382 patients with CRT and/or ICD referred for heart transplantation. American Heart Journal  , DOI: ( /j.ahj ) Copyright © 2014 Mosby, Inc. Terms and Conditions

3 Figure 2 Observed versus predicted event-free survival. Observed versus SHFM-predicted event-free survival at 1, 2, and 3 years in low-, medium-, and high-risk strata in 382 patients with CRT and/or ICD referred for heart transplantation. American Heart Journal  , DOI: ( /j.ahj ) Copyright © 2014 Mosby, Inc. Terms and Conditions

4 Figure 3 Calibration plot. Calibration plot showing the mean predicted probability of event-free survival against the observed proportion of event-free survival for the calculated SHFM integer score at 1, 2, and 3 years. The dashed line shows the ideal calibration line. American Heart Journal  , DOI: ( /j.ahj ) Copyright © 2014 Mosby, Inc. Terms and Conditions

5 Figure 4 Seattle Heart Failure Model score and predicted and observed survival. Distribution of the calculated SHFM integer score and its relationship to the predicted and observed survival in 382 patients with CRT and/or ICD referred for heart transplantation. American Heart Journal  , DOI: ( /j.ahj ) Copyright © 2014 Mosby, Inc. Terms and Conditions

Download ppt "Utility of the Seattle Heart Failure Model in patients with cardiac resynchronization therapy and implantable cardioverter defibrillator referred for."

Similar presentations

Validity of the LaFarge equation for estimation of oxygen consumption in ventilated children with congenital heart disease younger than 3 years—A revisit.

Validity of the LaFarge equation for estimation of oxygen consumption in ventilated children with congenital heart disease younger than 3 years—A revisit.
Effects of β-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal.

Effects of β-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal.
Downstream coronary effects of drug-eluting stents

Downstream coronary effects of drug-eluting stents
Comparison of Low Versus High (>40 mm Hg) Pulse Pressure to Predict the Benefit of Cardiac Resynchronization Therapy for Heart Failure (from the Multicenter.

Comparison of Low Versus High (>40 mm Hg) Pulse Pressure to Predict the Benefit of Cardiac Resynchronization Therapy for Heart Failure (from the Multicenter.
Journal of Cardiac Failure

Journal of Cardiac Failure
Identifying patients for advanced heart failure therapy by screening patients with cardiac resynchronization therapy or implantable cardioverter-defibrillator:

Identifying patients for advanced heart failure therapy by screening patients with cardiac resynchronization therapy or implantable cardioverter-defibrillator:
Quality of life and chronic heart failure therapy guided by natriuretic peptides: Results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy.

Quality of life and chronic heart failure therapy guided by natriuretic peptides: Results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy.
Balloon aortic valvuloplasty in the era of transcatheter aortic valve replacement: Acute and long-term outcomes  Hélène Eltchaninoff, MD, Eric Durand,

Balloon aortic valvuloplasty in the era of transcatheter aortic valve replacement: Acute and long-term outcomes  Hélène Eltchaninoff, MD, Eric Durand,
A clinically practicable diagnostic score for metabolic syndrome improves its predictivity of diabetes mellitus: The Gruppo Italiano per lo Studio della.

A clinically practicable diagnostic score for metabolic syndrome improves its predictivity of diabetes mellitus: The Gruppo Italiano per lo Studio della.
Ali Ahmed, MD, MPH, Gilbert J. Perry, MD, Jerome L. Fleg, MD, Thomas E

Ali Ahmed, MD, MPH, Gilbert J. Perry, MD, Jerome L. Fleg, MD, Thomas E
Previous coronary stents do not increase early and long-term adverse outcomes in patients undergoing off-pump coronary artery bypass grafting: A propensity-matched.

Previous coronary stents do not increase early and long-term adverse outcomes in patients undergoing off-pump coronary artery bypass grafting: A propensity-matched.
CHronic use of Amiodarone aGAinSt Implantable cardioverter-defibrillator therapy for primary prevention of death in patients with Chagas cardiomyopathy.

CHronic use of Amiodarone aGAinSt Implantable cardioverter-defibrillator therapy for primary prevention of death in patients with Chagas cardiomyopathy.
Incremental and independent value of cardiopulmonary exercise test measures and the Seattle Heart Failure Model for prediction of risk in patients with.

Incremental and independent value of cardiopulmonary exercise test measures and the Seattle Heart Failure Model for prediction of risk in patients with.
Can the Seattle Heart Failure Model Be Used to Risk-stratify Heart Failure Patients for Potential Left Ventricular Assist Device Therapy?  Wayne C. Levy,

Can the Seattle Heart Failure Model Be Used to Risk-stratify Heart Failure Patients for Potential Left Ventricular Assist Device Therapy?  Wayne C. Levy,
Variation among hospitals in selection of higher-cost, “higher-tech,” implantable cardioverter-defibrillators: Data from the National Cardiovascular Data.

Variation among hospitals in selection of higher-cost, “higher-tech,” implantable cardioverter-defibrillators: Data from the National Cardiovascular Data.
Automatic Optimization of Cardiac Resynchronization Therapy Using SonR—Rationale and Design of the Clinical Trial of the SonRtip Lead and Automatic AV-VV.

Automatic Optimization of Cardiac Resynchronization Therapy Using SonR—Rationale and Design of the Clinical Trial of the SonRtip Lead and Automatic AV-VV.
Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation  Anh L. Bui, MD, Maria.

Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation  Anh L. Bui, MD, Maria.
Risk reduction of cardiac events by screening of unknown asymptomatic coronary artery disease in subjects with type 2 diabetes mellitus at high cardiovascular.

Risk reduction of cardiac events by screening of unknown asymptomatic coronary artery disease in subjects with type 2 diabetes mellitus at high cardiovascular.
National evaluation of adherence to β-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance  Judith.

National evaluation of adherence to β-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance  Judith.
Rationale and design of a randomized clinical trial to assess the safety and efficacy of frequent optimization of cardiac resynchronization therapy: The.

Rationale and design of a randomized clinical trial to assess the safety and efficacy of frequent optimization of cardiac resynchronization therapy: The.

Similar presentations

Ads by Google